This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Unmet Need in Multiple MyelomaMode of ActionAboutMagentisMM-3 Study OverviewMagnetisMM-3 Study Design and Efficacy OutcomesMagnetisMM-3 Study Safety ProfileMagnetisMM-3 StudySafetyDosingMaterialsVideosSupport & Resources

The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.

ELREXFIO® is delivered in a ready-to-use*, single-dose vial for subcutaneous injection1

*ELREXFIO® is supplied as a ready-to-use solution that does not need dilution prior to administration. Aseptic technique should be used to prepare and administer ELREXFIO®.1

After step-up dosing, a full dose is administered weekly from Weeks 2-24 and then every 2 weeks from Week 25 onwards1

Pre-medication should be administered approximately 1 hour prior to the first three doses of ELREXFIO®, which includes step-up dose 1, step-up dose 2, and the first full treatment dose, to reduce the risk of CRS:1

  • Oral paracetamol 500 mg (or equivalent)
  • Oral diphenhydramine 25 mg (or equivalent)
  • Oral or IV dexamethasone 20 mg (or equivalent)

Due to the risk of cytokine release syndrome (CRS) and ICANS, patients should be monitored for signs and symptoms for 48 hours after administration of each step-up dose and instructed to remain within proximity of a healthcare facility.1

Patients can continue treatment with ELREXFIO® until disease progression or unacceptable toxicity.In the phase 2 MagnetisMM-3 study, 48.0% of BCMA-directed therapy-naïve patients (n=123) received ELREXFIO® treatment for at least 6 months.2

Dose reductions of ELREXFIO® are not recommended. Dose delays may be required to manage toxicities related to ELREXFIO®. Please refer to the ELREXFIO® Summary of Product Characteristics for dose delay guidelines.1

Administration1

ELREXFIO® should be administered subcutaneously by a healthcare provider with adequately trained medical personnel and appropriate medical equipment to manage severe reactions, including CRS and neurologic toxicity, including ICANS.1

Step 1

Step 2

Step 3

ELREXFIO® is supplied as a ready-to-use solution that does not need dilution prior to administration. Aseptic technique should be used to prepare and administer ELREXFIO®. The required dose of ELREXFIO® should be administered into the subcutaneous tissue of the abdomen, the preferred injection site. Alternatively, ELREXFIO® can be injected into the subcutaneous tissue of the thigh. Do not inject into areas where the skin is red, bruised, tender, hard or areas where there are scars.

Inspect the product for discolouration or particulate matter. The solution will be clear to slightly opalescent and colourless to pale brown. Do not administer the solution if it is discoloured or contains particulate matter.

ELREXFIO® should be prepared according to the preparation instructions. For each dose, draw the specified dosage from the vial and then discard the vial, even if it contains remaining solution.

Preparation instructions for ELREXFIO®

Preparation instructions for ELREXFIO®

Dose  Dose Volume            Vial          
12 mg (Step-up dose 1) 0.3 mL 44 mg
32 mg (Step-up dose 1) 0.8 mL 44 mg
76 mg (Full treatment dose) 1.9 mL 76 mg

Step 4

Step 5

Tab Number 3

Clean and prepare the injection site following proper aseptic technique before injecting all the liquid subcutaneously.

Dispose of the needle and needle cap appropriately into a sharps bin.

ReferencesDOs and DON'Ts when adminstering ELREXFIO®1 BCMA: B-cell maturation antigen; CAR: chimeric antigen receptor; CD38: cluster of differentiation 38; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; SmPC: Summary of Product Characteristics

References:

ELREXFIO® Summary of Product Characteristics. Click here for Great Britain. Click here for Northern Ireland.Lesohkin AM, et al. Nature Med. 2023;29(9):2259-2267.
Mode of actionELREXFIO® is a humanised BCMA-CD3-directed bispecific antibody Read moreLoadingELREXFIO® safety profileSafety profile of ELREXFIO® in all patients treated at the recommended dose in the Phase 2 MagnetisMM-3 study (n=183)  Read moreLoading
PP-L1A-GBR-0028. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​